I don't think its so irrational for the market or investors to get a little excited with IMU alongside the likes of Allogene and Poseida in a phase I trial progression for an allogeneic CAR T-cell therapy in its homeland.
The remarkable successes and rapid FDA approvals of new autologous CAR T-cell products in the treatment of patients with haematological malignancies is particularly inspiring. All the more credit that IMU are trialling in patients who such treatments have unfortunately failed too. The idea of IMU eventually being in the running for a commercial allogeneic treatment that gives hope to patients that even novel autologous therapies have failed, is pretty exicting.
Its been a horrible slog for longer term holders. Take the small win and enjoy a beer or two.
IMU Price at posting:
4.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)